<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2976-0526</journal-id>
<journal-title><![CDATA[Portuguese Kidney Journal (PKJ)]]></journal-title>
<abbrev-journal-title><![CDATA[PKJ]]></abbrev-journal-title>
<issn>2976-0526</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Nefrologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2976-05262024000200011</article-id>
<article-id pub-id-type="doi">10.71749/pkj.23</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and Treatment of Secondary Hyperparathyroidism in Pre -Dialysis Stages G3-G4 Chronic Kidney Disease: A Specialized Survey in Portugal]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[Ana Carina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brum]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coentrão]]></surname>
<given-names><![CDATA[Luís]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ULS São José - Hospital Curry Cabral Department of Nephrology ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Nova de Lisboa Faculdade de Ciências Médicas Department of Nephrology]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital do Santo Espírito da Ilha Terceira Department of Nephrology ]]></institution>
<addr-line><![CDATA[ Terceira, Azores]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro Hospitalar Universitário de São João Department of Nephrology ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Beatriz Ângelo Department of Nephrology ]]></institution>
<addr-line><![CDATA[Loures ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>2</numero>
<fpage>11</fpage>
<lpage>17</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2976-05262024000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2976-05262024000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2976-05262024000200011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: The clinical management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) stages G3&#8209;G4 patients currently faces several challenges. Although the understanding of SHPT has increased exponentially in recent years, many aspects regarding its diagnosis and management in non&#8209;dialysis G3&#8209;G4 CKD remain elusive. Specifically, while it is known that SHPT is linked to vitamin D insufficiency in pre&#8209;dialysis CKD patients, the target levels of vitamin D and parathyroid hormone, SHPT, and vitamin D monitoring and therapeutic guidelines are still to be clarified. It is, consequently, of utmost importance to generate data supporting consensual clinical decision&#8209;making and the implementation of evidence&#8209;based clinical practice guidelines.  Methods: Thus, a single&#8209;round Delphi&#8209;like study was conducted herein to assess the opinions and the level of agreement of 59 Portuguese nephrologists on the diagnosis and treatment of pre&#8209;dialysis G3&#8209;G4 CKD patients with SHPT.  Results: Although none of the statements under analysis gathered consensus, more than half of the statements regarding SHPT monitoring and therapeutics focusing on G3&#8209;G4 CKD achieved a qualified majority of agreement/disagreement. Overall, it may indicate a growing consensus trend among Portuguese nephrology specialists. Conversely, the heterogeneity of participants&#8217; opinions regarding the treatment of SHPT&#8209;associated vitamin D insufficiency reflects the heterogeneity in the knowledge in this specific field.  Conclusion: The results from this Delphi&#8209;like panel represent a first step towards improving the monitoring and therapeutic strategies concerning the prognosis of G3&#8209;G4 CKD patients, fostering unison among the Portuguese nephrology community.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Hyperparathyroidism, Secondary/diagnosis]]></kwd>
<kwd lng="en"><![CDATA[Hyperparathyroidism, Secondary/therapy]]></kwd>
<kwd lng="en"><![CDATA[Renal Insufficiency, Chronic]]></kwd>
<kwd lng="en"><![CDATA[Surveys and Questionnaires]]></kwd>
<kwd lng="en"><![CDATA[Vitamin D Deficiencyartment of Nephrology, Hospital Beatriz Ângelo, Loures, Portugal]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Locatelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary hyperparathyroidism pathogenesis, disease progression, and therapeutic options]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2011</year>
<volume>6</volume>
<page-range>913-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habas Sr]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Eledrisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Elzouki]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary Hyperparathyroidism in Chronic Kidney Disease Pathophysiology and Management]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2021</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Forging forward with 10 burning questions on FGF23 in kidney disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol,]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>1427-35</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rouached]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease results of the study to evaluate early kidney disease]]></article-title>
<collab>El Kadiri Boutchich S.Al Rifai AM.Garabédian M.Fournier A</collab>
<source><![CDATA[Kidney Int]]></source>
<year>2008</year>
<volume>74</volume>
<page-range>389-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stavroulopoulos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roe]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Hosking]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cassidy]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4]]></article-title>
<source><![CDATA[Nephrology]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>63-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andress]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Coyne]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Kalantar-Zadeh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Molitch]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Zangeneh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2008</year>
<volume>14</volume>
<page-range>18-27</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Kidney Disease: Improving Global Outcomes CKD-MBD Work Group</collab>
<article-title xml:lang=""><![CDATA[KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD -MBD)]]></article-title>
<source><![CDATA[Kidney Int Suppl]]></source>
<year>2009</year>
<volume>113</volume>
<page-range>S1-130</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group</collab>
<article-title xml:lang=""><![CDATA[KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease -Mineral and Bone Disorder (CKD -MBD)]]></article-title>
<source><![CDATA[Kidney Int Suppl]]></source>
<year>2017</year>
<volume>7</volume>
<page-range>1-59</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keung]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Perwad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D and kidney disease]]></article-title>
<source><![CDATA[Bone Rep]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>Rodríguez -Ortiz ME.Rodríguez M</collab>
<article-title xml:lang=""><![CDATA[Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2020</year>
<volume>9</volume>
<page-range>F1000</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>National Kidney Foundation</collab>
<article-title xml:lang=""><![CDATA[K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>S1-201</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doorenbos]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Possible renoprotection by vitamin D in chronic renal disease beyond mineral metabolism]]></article-title>
<collab>van den Born J.Navis G.de Borst MH</collab>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2009</year>
<volume>5</volume>
<page-range>691-700</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sp368chronic Kidney Disease Mineral Bone Disorder in Korean Patients a Report from the Know-Ckd]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2017</year>
<volume>32</volume>
<page-range>iii236</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandenburg]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ketteler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease A Critical Appraisal of the Past, Present, and the Future]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>3009</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Con Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2021</year>
<volume>36</volume>
<page-range>566-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roizen]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Casella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity Decreases Hepatic 25 -Hydroxylase Activity Causing Low Serum 25 -Hydroxyvitamin D]]></article-title>
<collab>O'Lear L.Caplan I.Lai M</collab>
<source><![CDATA[J Bone Miner Res]]></source>
<year>2019</year>
<volume>34</volume>
<page-range>1068-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Pergola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zupo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caccavo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pecorella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Paradiso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects]]></article-title>
<source><![CDATA[Endocr Metab Immune Disord Drug Targets]]></source>
<year>2019</year>
<volume>19</volume>
<page-range>838-44</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saneei]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salehi-Abargouei]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Esmaillzadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum 25 -hydroxy vitamin D levels in relation to body mass index a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Obes Rev]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>393-404</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tebben]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D-Mediated Hypercalcemia Mechanisms, Diagnosis, and Treatment]]></article-title>
<source><![CDATA[Endocr Rev]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>521</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petkovich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Melnick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tabash]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Strugnell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modified -release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation]]></article-title>
<source><![CDATA[J Steroid Biochem Mol Biol]]></source>
<year>2015</year>
<volume>148</volume>
<page-range>283-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Melnick]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Strugnell]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mangoo-Karim]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Extended -Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2016</year>
<volume>44</volume>
<page-range>316-25</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Strugnell]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended -release calcifediol for secondary hyperparathyroidism in stage 3 -4 chronic kidney disease]]></article-title>
<source><![CDATA[Expert Rev Endocrinol Metab]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>289-301</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modified -release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease]]></article-title>
<collab>Al -Saghir F.Damle R.Tabash SP.Petkovich M</collab>
<source><![CDATA[Am J Nephrol]]></source>
<year>2014</year>
<volume>40</volume>
<page-range>535-45</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strugnell]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ashfaq]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Petkovich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale for Raising Current Clinical Practice Guideline Target for Serum 25 -Hydroxyvitamin D in Chronic Kidney Disease]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2019</year>
<volume>49</volume>
<page-range>284-93</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ennis]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Worcester]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Coe]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Sprague]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low]]></article-title>
<source><![CDATA[J Nephrol]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>63-70</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nemeth]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological regulation of parathyroid hormone secretion]]></article-title>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2002</year>
<volume>8</volume>
<page-range>2077-87</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chonchol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Locatelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abboud]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Charytan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de Francisco]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Jolly]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2009</year>
<volume>53</volume>
<page-range>197-207</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomasello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary Hyperparathyroidism and Chronic Kidney Disease]]></article-title>
<source><![CDATA[Diabetes Spect]]></source>
<year>2008</year>
<volume>21</volume>
<page-range>19-125</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cernaro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lacquaniti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costantino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Visconti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Buemi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phospate binders for the treatment of chronic kidney disease role of iron oxyhydroxide]]></article-title>
<source><![CDATA[Int J Nephrol Renovasc Dis]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>11-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thadhani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Appelbaum]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pritchett]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wenger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tamez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease the PRIMO randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2012</year>
<volume>307</volume>
<page-range>674-84</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Qing]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of paricalcitol on left ventricular mass and function in CKD - -the OPERA trial J Am Soc Nephrol. 2014;25175 -86. doi: 10.1681/ASN.2013010103]]></article-title>
<source><![CDATA[Erratum in: J Am Soc Nephrol]]></source>
<year>2019</year>
<volume>30</volume>
<page-range>516</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashfaq]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Germain]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Broumand]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fadda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[P0901real-World Assessment: Clinical Effectiveness and Safety of Vitamin D Therapies in Nd-Ckd Patients]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2020</year>
<volume>35</volume>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cozzolino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ketteler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD -MBD)]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>2081-93</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aikens]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[McNabb]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of the diabetes problem-solving measure for adolescents]]></article-title>
<source><![CDATA[Diabetes Educ]]></source>
<year>2001</year>
<volume>27</volume>
<page-range>865-74</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chadwick]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the acceptability of a 'limited patient consent procedure' for a proposed blood -borne virus screening programme a Delphi consensus building technique]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Kagan]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>1998</year>
<volume>40</volume>
<page-range>1117-24</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wainwright]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tompsett]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of vignettes within a Delphi exercise: a useful approach in empirical ethics?]]></article-title>
<source><![CDATA[J Med Ethics]]></source>
<year>2010</year>
<volume>36</volume>
<page-range>656-60</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wigton]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Darr]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Corbett]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Nickol]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How do community practitioners decide whether to prescribe antibiotics for acute respiratory tract infections]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2008</year>
<volume>23</volume>
<page-range>1615</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[We Agree, Don't We The Delphi Method for Health Environments Research]]></article-title>
<source><![CDATA[HERD]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>11-23</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
